BBHC
DNLI icon

Brown Brothers Harriman & Co’s Denali Therapeutics DNLI Stock Holding History

Brown Brothers Harriman & Co’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,524
Closed -$45K – 1521
2022
Q2 		$45K Sell
1,524
-500
-25% -$13.1K ﹤0.01% 725
2022
Q1 		$65K Sell
2,024
-7,000
-78% -$241K ﹤0.01% 717
2021
Q4 		$402K Buy
9,024
+6,524
+261% +$309K ﹤0.01% 367
2021
Q3 		$126K Sell
2,500
-3,553
-59% -$200K ﹤0.01% 528
2021
Q2 		$475K Buy
6,053
+5,000
+475% +$309K ﹤0.01% 323
2021
Q1 		$60K Sell
1,053
-17
-2% -$1.14K ﹤0.01% 615
2020
Q4 		$90K Buy
+1,070
New +$64.7K ﹤0.01% 574
2020
Q1 		– Sell
-2,316
Closed -$40K – 1144
2019
Q4 		$40K Hold
2,316
– – ﹤0.01% 705
2019
Q3 		$35K Hold
2,316
– – ﹤0.01% 704
2019
Q2 		$48K Hold
2,316
– – ﹤0.01% 591
2019
Q1 		$54K Hold
2,316
– – ﹤0.01% 563
2018
Q4 		$48K Buy
+2,316
New +$42K ﹤0.01% 517

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Brown Brothers Harriman & Co's DNLI Position: Q3 2022 in Review

Brown Brothers Harriman & Co sold out of Denali Therapeutics (DNLI) in Q3 2022, closing a stake of 1,524 shares — an estimated $45K sold.

Brown Brothers Harriman & Co first reported a position in DNLI in Q4 2018 and held it in 12 quarters. The position peaked at $475K in Q2 2021. 200 funds tracked by Wall St. Rank hold DNLI as of Q3 2022.

  • Brown Brothers Harriman & Co reported no remaining Denali Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 1,524 Denali Therapeutics shares in Q3 2022, an estimated $45K.
  • Brown Brothers Harriman & Co first reported a position in Denali Therapeutics in Q4 2018 and held it in 12 quarters.
  • Brown Brothers Harriman & Co's Denali Therapeutics position peaked at $475K in Q2 2021.
  • 200 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q3 2022, filed 14 Nov 2022.